Anjana Bose

Summary

Affiliation: Forest Research Institute
Country: USA

Publications

  1. doi request reprint Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine
    Anjana Bose
    Forest Research Institute, Jersey City, NJ 07311, USA
    Clin Drug Investig 32:373-85. 2012
  2. doi request reprint Escitalopram in the acute treatment of depressed patients aged 60 years or older
    Anjana Bose
    Forest Research Institute, Harborside Financial Center, Jersey City, NJ 07311, USA
    Am J Geriatr Psychiatry 16:14-20. 2008
  3. ncbi request reprint Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder
    Anjana Bose
    Forest Laboratories, Harborside Financial Center, Jersey City, New Jersey, USA
    Depress Anxiety 25:854-61. 2008
  4. ncbi request reprint Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, USA
    J Clin Psychiatry 67:1767-75. 2006
  5. ncbi request reprint Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder
    Jonathan R T Davidson
    Department of Psychiatry and Behavioral Science, Duke University Medical Center, Box 3812, Durham, N C 27710, USA
    J Clin Psychiatry 66:1441-6. 2005
  6. ncbi request reprint A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder
    Robert J Bielski
    Summit Research Network, 4084 Okemos Road Suite C, Okemos, MI 48864, USA
    Ann Clin Psychiatry 17:65-9. 2005
  7. ncbi request reprint Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials
    Wayne K Goodman
    Department of Psychiatry, University of Florida, PO Box 100256, Gainesville, FL 32610, USA
    J Affect Disord 87:161-7. 2005
  8. ncbi request reprint Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study
    Jonathan R T Davidson
    Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, NC 27710, USA
    Depress Anxiety 19:234-40. 2004
  9. ncbi request reprint Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
  10. ncbi request reprint Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients
    William J Burke
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198 5580, USA
    J Clin Psychiatry 63:331-6. 2002

Detail Information

Publications13

  1. doi request reprint Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine
    Anjana Bose
    Forest Research Institute, Jersey City, NJ 07311, USA
    Clin Drug Investig 32:373-85. 2012
    ..It is often unclear whether relevant tolerability and efficacy differences exist between SSRI up-titration versus switch to an SNRI...
  2. doi request reprint Escitalopram in the acute treatment of depressed patients aged 60 years or older
    Anjana Bose
    Forest Research Institute, Harborside Financial Center, Jersey City, NJ 07311, USA
    Am J Geriatr Psychiatry 16:14-20. 2008
    ..The present study examined the efficacy and tolerability of acute escitalopram treatment in depressed patients aged 60 years or older...
  3. ncbi request reprint Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder
    Anjana Bose
    Forest Laboratories, Harborside Financial Center, Jersey City, New Jersey, USA
    Depress Anxiety 25:854-61. 2008
    ..However, overall efficacy analyses suggest that escitalopram and venlafaxine XR are both effective treatments for GAD. Escitalopram was better tolerated...
  4. ncbi request reprint Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial
    Susan G Kornstein
    Department of Psychiatry, Virginia Commonwealth University, Richmond, USA
    J Clin Psychiatry 67:1767-75. 2006
    ..The current trial examined the efficacy of maintenance escitalopram treatment in preventing depression recurrence in patients who responded to acute SSRI therapy...
  5. ncbi request reprint Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder
    Jonathan R T Davidson
    Department of Psychiatry and Behavioral Science, Duke University Medical Center, Box 3812, Durham, N C 27710, USA
    J Clin Psychiatry 66:1441-6. 2005
    ..Generalized anxiety disorder (GAD) is a chronic disorder that requires long-term treatment. Escitalopram has previously been shown to be effective and well tolerated in the acute treatment of GAD...
  6. ncbi request reprint A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder
    Robert J Bielski
    Summit Research Network, 4084 Okemos Road Suite C, Okemos, MI 48864, USA
    Ann Clin Psychiatry 17:65-9. 2005
    ..This study compared the efficacy and tolerability of escitalopram, a newer SSRI, with paroxetine in the treatment of generalized anxiety disorder (GAD)...
  7. ncbi request reprint Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials
    Wayne K Goodman
    Department of Psychiatry, University of Florida, PO Box 100256, Gainesville, FL 32610, USA
    J Affect Disord 87:161-7. 2005
    ..Escitalopram 10 mg/day is an effective and well-tolerated antidepressant. Three randomized controlled trials recently evaluated the safety and efficacy of escitalopram in the treatment of generalized anxiety disorder (GAD)...
  8. ncbi request reprint Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study
    Jonathan R T Davidson
    Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, NC 27710, USA
    Depress Anxiety 19:234-40. 2004
    ..9% vs. 5.1%; P=.27). Escitalopram 10-20 mg/day is effective, safe, and well tolerated in the treatment of patients with GAD...
  9. ncbi request reprint Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
    ..Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment...
  10. ncbi request reprint Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients
    William J Burke
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198 5580, USA
    J Clin Psychiatry 63:331-6. 2002
    ..The present randomized, double-blind, placebo-controlled, fixed-dose multicenter trial was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of major depressive disorder...
  11. ncbi request reprint Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting
    A John Rush
    University of Texas Southwestern Medical Center at Dallas, Department of Psychiatry, Dallas, Texas 75390 9086, USA
    Depress Anxiety 21:26-32. 2005
    ..Overall, 9% of patients discontinued due to adverse events. Escitalopram treatment was well tolerated and associated with robust response rates in a broadly representative population of depressed outpatients...
  12. ncbi request reprint Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Clin Drug Investig 27:481-92. 2007
    ..This study evaluated the efficacy and safety of escitalopram versus duloxetine in the acute treatment of patients with moderate to severe major depressive disorder...
  13. ncbi request reprint Naturalistic study of the early psychiatric use of citalopram in the United States
    A John Rush
    The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390 9086, USA
    Depress Anxiety 16:121-7. 2002
    ..8%, whereas those without such a history had a discontinuation rate of 13.3%. Citalopram administered at an average dose of 23.6 mg/day was associated with favorable outcomes and was generally well tolerated...